TP53 and cancer: Although not noted as a common effect, there are examples of a link between oncogene action and down-regulation of the wild-type TP53; among others, they include overexpression of HER-2/neu in breast cancer cell lines, NPM-ALK fusion protein in ALK-expressing lymphoma, cancer associated fibroblasts, and interestingly, another FGFR3-fusion protein, FGFR3–BAIAP2L1, where evidence has been based on a comprehensive gene expression analysis [35, 44–46].